Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
ConclusionsIcosapent ethyl is cost effective for primary and secondary cardiovascular prevention at an annual price of £2064 in the UK. For PCSK9 inhibitors, price discounts or prescription restrictions are necessary to achieve cost effectiveness.Graphical abstract
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Drugs & Pharmacology | Fenofibrate | Heart | Heart Attack | Omega 3 | Statin Therapy | Stroke | Tricor | UK Health | Vytorin | Zetia